Curated News
By: NewsRamp Editorial Staff
October 28, 2026
Immunotherapy Combo Nearly Doubles Lung Cancer Survival in Phase 3 Trial
TLDR
- Combining two immunotherapies nearly doubled median survival in deadly lung cancer, giving Amgen and partners a competitive edge in oncology.
- A Phase 3 trial of 563 patients tested two immunotherapy drugs together, showing extended survival versus standard care, published in NEJM.
- This immunotherapy combination offers new hope for patients with one of the deadliest lung cancers, potentially improving survival and quality of life.
- Learn how combining two immunotherapy drugs extended survival in a Phase 3 lung cancer trial, presented at ESMO and published in NEJM.
Impact - Why it Matters
The trial results offer a rare bright spot in the fight against one of the deadliest cancers, where treatment options have historically been limited and prognosis poor. For patients and their families, the near-doubling of median survival represents a meaningful step forward that could soon translate into new clinical options. The data also validate the broader promise of immunotherapy, encouraging further investment and research into combination approaches that may extend benefits to other hard-to-treat cancers. As companies like Calidi Biotherapeutics advance their own immunotherapy candidates, the landscape of cancer care could shift toward more durable, less toxic treatments. Ultimately, this news matters because it signals that innovative science is delivering tangible survival gains, and the momentum is likely to accelerate as more therapies reach the market.
Summary
A combination of two immunotherapy drugs has significantly extended survival in patients with one of the deadliest forms of lung cancer, with trial data showing median survival nearly doubling against the current standard of care. Results from the Phase 3 study involving 563 patients were presented during a conference of the European Society for Medical Oncology in Madrid and also published simultaneously in the New England Journal of Medicine. The news underscores the growing momentum behind immunotherapy as a transformative approach to cancer treatment.
Immunotherapy is proving to be transformative in cancer treatment, and there is hope that more of these treatments are going to be brought to market by companies like Calidi Biotherapeutics Inc. (NYSE American: CLDI) so that more cancer types can benefit from similar advances. The trial results represent a potential paradigm shift for patients with limited options, and the broader industry is watching closely as novel immunotherapies move through development pipelines.
The announcement was distributed through TinyGems, a specialized communications platform focused on innovative small-cap and mid-cap companies with bright futures and huge potential. TinyGems is one of 75+ brands within the Dynamic Brand Portfolio @ IBN, which provides access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution to millions of followers, and a full array of tailored corporate communications solutions. For more details, readers can Read More>>.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Immunotherapy Combo Nearly Doubles Lung Cancer Survival in Phase 3 Trial
